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Summary
Background Publication of the JUPITER trial has renewed the interest in the use of CRP in cardiovascular risk 
prediction. The aim of the study was to assess the relationship between CRP, ambulatory blood pressure and target 
organ damage in a cohort of treated hypertensive males without overt cardiovascular disease. 
Materials and methods The studied group consisted of 299 male hypertensive patients. Patients were stratified into 
low (≤ 2 mg/L), intermediate (2–5 mg/L), and high (> 5 mg/L) CRP groups. We measured ambulatory blood pressure, 
pulse wave velocity, left ventricular function and structure, carotid intima media thickness and ankle-brachial index. 
Results Twenty-six percent of the patients had CRP in the range of 2 to 5 mg/L, and 12% had CRP levels exceeding 
5 mg/L. Ambulatory blood pressure and heart rate were not different across the three groups. Patients with high CRP 
had lower HDL cholesterol levels and higher plasma fibrinogen levels. Carotid femoral pulse wave velocity, carotid 
intima media thickness and ankle-brachial index were not different across the three groups. Echocardiographic data 
were also not related to the CRP level. 
Conclusions
1. Elevated levels of CRP are frequently observed among treated patients with hypertension.
2. CRP elevation is associated with higher fibrinogen and glucose levels, and lower HDL cholesterol independently 
of obesity and smoking status.
3. Elevated CRP levels are not related to ambulatory blood pressure profile or target organ damage severity.
4. Our findings are consistent with the concept that CRP measurement is of limited value in cardiovascular assessment. 
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Background
There is growing evidence supporting a role of 
inflammation and immunity in hypertension [1]. 
High-sensitivity C-reactive protein (CRP) has re-
ceived the most attention among inflammatory bio-
markers for its potential use in cardiovascular risk 
assessment [2]. Based on early studies linking high 
CRP to increased incidence of cardiovascular events 
in several clinical settings [3], its measurement in pa-
tients with arterial hypertension was recommended 
by the 2003 ESH/ESC guidelines [4]. More recent 
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studies [5] questioned added value of CRP in de-
termining total cardiovascular risk. Consequently, 
the recommendation to measure CRP routinely in 
hypertensive patients was not sustained in the 2007 
ESH/ESC guidelines [6].
Publication of the JUPITER trial [7] has renewed 
the interest in the use of CRP in cardiovascular risk 
prediction. The trial, which randomized 17,802 pa-
tients with CRP > 2 mg/L to rosuvastatin 20 mg ver-
sus placebo, was stopped early due to a robust 44% 
relative risk reduction in the primary endpoint. The 
risk reduction was directly related to baseline CRP 
levels [8]. Therefore, most of the recent CRP-related 
research efforts focused on its role as a predictor 
of clinical response to statin therapy. Much less is 
known about the importance of CRP in hyperten-
sion, especially in the setting of the antihypertensive 
therapy. Therefore, we assessed the relationship be-
tween CRP, ambulatory blood pressure and target 
organ damage in a cohort of treated hypertensive 
males without overt cardiovascular disease. 
Materials and methods
Subjects
We studied 299 male hypertensive patients, aged 
19 to 75 years, with essential hypertension, recruited 
from the outpatient clinic of the Department of 
Hypertension and Diabetology, Medical University 
of Gdansk. The patients were free of cardiovascular 
disease and diabetes. We have excluded patients with 
any acute disease potentially affecting the CRP level. 
The study was approved by the Institutional Human 
Subjects Review Committee. Informed written con-
sent was obtained from all patients.
Measurements
Twenty-four hour ambulatory blood pressure and 
heart rate monitoring (ABPM) was performed with 
the Spacelabs 90207 recorder (Spacelabs Inc.). The 
recorders were programmed to obtain measurements 
every 20 minutes from 6 AM to 10 PM, and every 
30 minutes from 10 PM to 6 AM. Subjects were 
asked to continue their regular activities during the 
recordings, and to go to bed not later than 11 PM. 
The daytime period was defined as the interval from 
8 AM to 10 PM, and nighttime as the interval from 
midnight to 6 AM. 
Carotid femoral pulse wave velocity (PWV) was 
measured with the Sphygmocor AtCor 232 device 
following the expert consensus document on the 
measurement of aortic stiffness in daily practice [9]. 
Carotid intima media thickness (IMT) was assessed 
using the ArtLab system (ArtLab, Esaote, Italy). 
Ankle-brachial index (ABI) was measured with the 
Minidop ES-100VX device (Hadeco Inc., Japan). 
Transthoracic echocardiographic recordings (Vivid 
7 Pro™ GE; 2.0–3.6 MHz transducer) were obtained 
during quiet breathing after several minutes of rest. 
The following structural and functional heart pro-
perties were recorded according to American So-
ciety of Echocardiography [10] recommendations: 
left ventricle (LV) mass index, relative wall thickness 
(RWT), ejection fraction (LVEF), early (E) and atrial 
(A) trans-mitral flow velocities, and their ratio (E/A). 
High-sensitive plasma CRP in mg/L was measured 
by the commercially available system (Roche Diag-
nostics Corp, Indianapolis, IN),
Statistical analysis
Results are expressed as means ± SD. Patients were 
stratified into low (≤ 2 mg/L), intermediate (2–5 mg/ 
/L), and high (> 5 mg/L) CRP groups. Comparisons 
between the three groups were made by an analysis 
of variance (ANOVA) and analysis of the covariance 
(ANCOVA) followed by Scheffe’s test for multiple 
comparisons. Fisher’s exact test was used to determine 
differences in categorical variables between groups. All 
data were computed using Statistica 10 (StatSoft Inc). 
A P < 0.05 was considered significant. 
Results
Twenty-six percent of the patients had CRP in 
the range of 2 to 5 mg/L, and 12% had CRP levels 
exceeding 5 mg/L (Figure 1). 
Baseline characteristics of the patients grouped ac-
cording to the CRP levels are provided in Table I. Pa-
tients with low CRP were less obese and were less likely 
to smoke. The three groups were comparable in terms 
of age and number of antihypertensive medications. 
Ambulatory blood pressure and heart rate were 
not different across the three groups (Table II). 
Table III presents laboratory findings of the patients 
subdivided according to the CRP levels. Patients with 
the low CRP levels had lower fasting plasma glucose 
than those with CRP > 2 mg/L. Patients with high CRP 
had lower HDL cholesterol levels and higher plasma 
fibrinogen levels (Table III). These differences remained 
significant after adjustment for body mass index, waist- 
-to-hip ratio and smoking status (Figures 2 and 3). 
Carotid femoral pulse wave velocity, carotid inti-
ma media thickness and ankle-brachial index were 
not different across the three groups (Table IV). 
Echocardiographic data were also not related to the 
CRP level (Table V). 
Michał Hoffmann et al. CRP, blood pressure and target organ damage
47www.ah.viamedica.pl
Table I. Demographic data in patients grouped according to the CRP level
CRP 
< 2 mg/L 
CRP
2–5 mg/L 
CRP
> 5 mg/L
P
Age (years) 47.4 ± 14.2 49.6 ± 13.4 48.6 ± 15.6 0.52
BMI [kg/m2] 28.4 ± 3.8 30.0 ± 4.6* 30.8 ± 6.2* < 0.001
Waist-to-hip ratio 0.96 ± 0.07 1.00 ± 0.06* 0.98 ± 0.08* < 0.001
Number of drugs 2.5 ± 1.5 2.9 ± 1.7 2.8 ± 1.2 0.08
Smoking (%) 12.9 28.2 16.2 0.01
Table II. Ambulatory blood pressure and heart rate in patients grouped according to the CRP level
CRP 
< 2 mg/L 
CRP
2–5 mg/L 
CRP
> 5 mg/L
P
SBP daytime [mmHg] 132.9 ± 10.6 133.9 ± 11.3 133.5 ± 12.0 0.76
SBP nighttime [mmHg] 117.2 ± 11.3 120.2 ± 12.2 119.3 ± 12.3 0.14
DBP daytime [mmHg] 81.5 ± 7.9 81.0 ± 8.1 81.5 ± 10.8 0.89
DBP nighttime [mmHg] 68.8 ± 8.4 69.9 ± 8.8 70.6 ± 11.6 0.42
HR daytime (bpm) 74.3 ± 9.2 75.5 ± 9.9 75.7 ± 12.6 0.14
HR nighttime (bpm) 61.7 ± 8.1 64.1 ± 8.6 63.5 ± 8.5 0.08
Figure 1. Distribution of patients grouped according to the CRP level
Table III. Unadjusted laboratory data in patients grouped according to the CRP level
CRP 
< 2 mg/L 
CRP
2–5 mg/L 
CRP
5 mg/L
P
Fasting glucose [mg/dL] 96.7 ± 10.7 102.4 ± 12.7* 101.3 ± 12.6* < 0.001
LDL cholesterol [mg/dL] 123.6 ± 34.6 129.7 ± 34.1 121.3 ± 41.0 0.36
HDL cholesterol [mg/dL] 47.7 ± 11.8 44.5 ± 11.9 41.5 ± 14.3* 0.007
Triglycerides [mg/dL] 133.8 ± 77.3 145.9 ± 75.7 140.0 ± 60.2 0.48
eGFR [ml/min/1.73 m2] 96.8 ± 19.6 98.0 ± 16.0 92.7 ± 24.6 0.38
Fibrinogen [g/L] 2.8 ± 0.7 3.2 ± 1.1 4.0 ± 1.5*, ** < 0.001
Discussion
The main findings in this study are first, that ele-
vated levels of CRP are frequently observed among 
patients with hypertension despite antihypertensive 
treatment and reasonable blood pressure control. Se-
cond, CRP elevation is associated with lower HDL 
cholesterol and higher fibrinogen independently of 
obesity and smoking status. Third, elevated CRP levels 
are not related to ambulatory blood pressure profile or 
target organ damage severity. Thus, our data do not 
support the concept that CRP elevation may trigger 
cardiovascular events in treated patients by alteration 
of blood pressure diurnal profile or by potentiating 
hypertension-related cardiovascular damage. 
More than one third of our patients had CRP lev-
els above 2 mg/L. High prevalence of elevated CRP 
is consistent with the results of the 2002 NATPOL 
PLUS survey (Nadciśnienie Tętnicze w Polsce Plus 
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Table IV. Ankle-brachial index (ABI), carotid-femoral pulse wave velocity (PWV) and carotid intima-media thickness (IMT) in patients  
grouped according to the CRP level
CRP 
< 2 mg/L 
CRP
2–5 mg/L 
CRP
> 5 mg/L
P
ABI 1.14 ± 0.11 1.14 ± 0.14 1.11 ± 0.12 0.52
PWV [m/s] 9.7 ± 2.0 10.0 ± 2.0 9.8 ± 1.7 0.51
IMT [mm] 0.65 ± 0.16 0.66 ± 0.13 0.68 ± 0.17 0.44
Table V. Echocardiographic data in patients grouped according to the CRP level
CRP 
< 2 mg/L 
CRP
2–5 mg/L 
CRP
> 5 mg/L
P
LVMI [g/m2] 115.4 ± 26.2 107.8 ± 23.5 118.0 ± 32.6 0.06
RWT 0.50 ± 0.07 0.50 ± 0.08 0.48 ± 0.07 0.20
EF (%) 69.5 ± 8.1 70.5 ± 7.6 67.3 ± 7.6 0.18
E [m/s] 73.2 ± 15.6 73.5 ± 16.8 75.6 ± 15.2 0.76
A [m/s] 68.4 ± 13.8 70.4 ± 14.3 70.2 ± 19.0 0.60
E/A 1.11 ± 0.32 1.09 ± 0.35 1.15 ± 0.36 0.75
Figure 2. HDL cholesterol in patients grouped according to the CRP 
level after adjustment for body mass index, waist to hip ratio and 
smoking status. *P < 0.05 vs. patients with CRP < 2 mg/L (analy-
sis of covariance)
Figure 3. Plasma fibrinogen levels in patients grouped according to the 
CRP level after adjustment for body mass index, waist to hip ratio and 
smoking status. *P < 0.001 vs. patients with CRP < 2 mg/L; *P < 0.01 
vs. patients with CRP levels between 2 and 5 mg/L (analysis of covariance)
Zaburzenia Lipidowe i Cukrzyca — Arterial Hyper-
tension in Poland Plus Lipid Disorders and Diabe-
tes) reporting increased level of CRP (defined as > 
1 mg/L) in 52% of adult males and in 62% of male 
hypertensives in Poland [11]. In the present study, 
we have used the CRP cut-off point of 2 mg/L 
similarly to that used in the JUPITER trial [7]. 
Furthermore, such classification is consistent with 
the ARIC (Atherosclerosis Risk in Communities) 
study, in which patients with CRP > 2 mg/L had 
a higher risk of CV events than individuals with low 
CRP level [12].
We were able to confirm results of earlier studies 
showing that elevated CRP is independently linked 
to higher plasma fibrinogen and glucose levels, and to 
lower HDL cholesterol levels, which can trigger both 
atherosclerosis and acute cardiovascular events [2].
The results of the previous studies linking CRP to 
arterial stiffness [13–17] and carotid intima-media 
thickness [18–22] are not consistent. Discrepancies 
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in the results of earlier studies might be explained by 
a number of factors including presence of co-mor-
bidities and previous treatment, age of the studied 
subjects and methodological aspects. In our study, 
we were not able to demonstrate any relationship 
between CRP and vascular damage in treated hy-
pertensive patients. Our findings are in agreement 
with the results of another Polish study performed in 
untreated patients [17]. Similarly to our study, Syp-
niewska et al. [17] were not able to document and 
link between CRP and left ventricular mass index. 
The novel finding of our study is lack of the relation-
ship between CRP and left ventricular function. 
Our study was limited to males. The relationship 
between CRP, ambulatory blood pressure and target 
organ damage may be different in females. We did 
not assess endothelial function, which could provide 
further insights into relationship between inflamma-
tion and cardiovascular damage. In mitigation, we 
have carefully applied all methods of cardiovascu-
lar phenotyping suggested by the 2013 ESH/ESC 
guidelines [23]. Furthermore, we measured ambula-
tory blood pressure in all patients excluding white-
coat hypertension. 
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Conclusions
1. Elevated levels of CRP are frequently observed 
among treated patients with hypertension.
2. CRP elevation is associated with higher fi-
brinogen and glucose levels, and lower HDL 
cholesterol independently of obesity and smo-
king status. 
3. Elevated CRP levels are not related to ambu-
latory blood pressure profile or target organ 
damage severity.
4. Our findings are consistent with the concept 
that CRP measurement is of limited value in 
cardiovascular assessment. 
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